Retatrutide vs Tirzepatide
The triple agonist beats the dual agonist on paper. Is it worth waiting for, or buying early?
Reviewed by the amino101 editorial team. , first published .
Retatrutide and tirzepatide are both Eli Lilly peptides, both injected once weekly, and both built on the same incretin idea. Tirzepatide activates GLP-1 and GIP receptors and is approved as Mounjaro and Zepbound. Retatrutide adds a third receptor, glucagon, and is not approved anywhere. The glucagon component raises energy expenditure and pushes the liver to burn fat, which is why retatrutide posts bigger numbers: about 24 percent weight loss at 48 weeks in phase 2, and in 2026 Lilly reported a TRIUMPH-1 topline figure of roughly 28 percent over 80 weeks at 12 mg, against tirzepatide's 20.9 percent at 72 weeks in SURMOUNT-1. Those retatrutide figures are sponsor reported and pending full publication. The trade is evidence and safety for effect size. Tirzepatide has years of real world use and an established safety profile. Retatrutide has a heart rate signal that tirzepatide does not, no approved product, and a grey market full of faked vials. This page is an educational comparison, not a treatment plan.
| Retatrutide | Tirzepatide | |
|---|---|---|
| Typical dosage | 1 to 2 mg (starting dose) | 2.5 mg (starting dose) |
| Frequency | once weekly | once weekly |
| Route | Subcutaneous | Subcutaneous |
| Half-life | About 6 days (phase 1 estimate) | About 5 days (roughly 117 hours) |
| Cycle | ongoing in trials, escalated every 4 weeks toward 4, 8 or 12 mg | ongoing, increase by 2.5 mg every 4 weeks as tolerated |
| Research level | Extensively studied | Extensively studied |
| Human trials | Randomized trials | Approved drug |
| Status | Investigational, in Phase 3 trials. Not FDA approved anywhere. | FDA approved as Mounjaro and Zepbound. Grey-market vials are not the approved product. |
| Effects timeline | appetite drop within 1 to 2 weeks, resting heart rate rise in the first month, weight loss builds from about week 4 and was still going at 48 weeks in phase 2 | appetite drops within the first 1 to 2 weeks, weight loss builds from about week 4, plateau around 12 to 18 months |
Key differences
Retatrutide vs Tirzepatide dosage
Dosage patterns reported in research and community protocols, by goal. Taken from each compound page. Not a prescription.
| Goal | Dosage | Frequency |
|---|---|---|
| Weeks 1 to 4, tolerance | 1 to 2 mg | once weekly |
| Weeks 5 to 8 | 2 to 4 mg | once weekly |
| Weeks 9 to 12 | 4 to 8 mg | once weekly |
| Week 13 onward, if still needed | 8 to 12 mg | once weekly |
| Low-dose hold (common community pattern) | 4 mg | once weekly |
| Goal | Dosage | Frequency |
|---|---|---|
| Weeks 1 to 4, tolerance | 2.5 mg | once weekly |
| Weeks 5 to 8 | 5 mg | once weekly |
| Weeks 9 to 12 | 7.5 mg | once weekly |
| Weeks 13 to 16 | 10 mg | once weekly |
| Week 17 onward, if still needed | 12.5 to 15 mg | once weekly |
Convert any of these to syringe units in the dosage calculator.
Side effects compared
- ▲Nausea, vomiting and diarrhea, rougher than semaglutide in the early weeks
- ▲Resting heart rate up by several beats per minute for the first months
- ▲Skin tingling or heightened skin sensitivity (dysesthesia)
- ▲Constipation and reflux
- ▲Injection site reactions
- ▲Nausea and reduced appetite, worst right after each dose increase
- ▲Diarrhea or constipation
- ▲Burping, reflux and indigestion
- ▲Fatigue during the first weeks of each step
- ▲Injection site reactions
Which should you choose?
Retatrutide fits someone who has already run tirzepatide to 15 mg, plateaued, and accepts an unapproved compound from a market where purity varies vial to vial. The glucagon component adds a calories out lever that tirzepatide does not have, which is where the extra weight loss comes from. It is not the right first GLP-1 drug for anyone. The retatrutide dosage chart covers the 1 or 2 mg trial starting doses.
Tirzepatide fits almost everyone else. It is approved, available as branded pens and Lilly direct vials, and it produced about 20 percent weight loss with a tolerable side effect profile in SURMOUNT-1. The GIP component appears to blunt nausea relative to semaglutide. Start with the tirzepatide dosage chart for the 2.5 mg step schedule.
If you need a result now, tirzepatide. It is approved, the SURMOUNT program is published, and the gap in weight loss between the two is real but smaller than the gap in evidence. Retatrutide is the better molecule on paper and will probably be the stronger drug once it is approved, but that is not expected before late 2027, and what is sold today is unverified powder with the extra heart rate signal and no long term safety data. The people for whom retatrutide makes sense are those already comfortable with grey market sourcing and batch testing who have plateaued on tirzepatide at 15 mg. Everyone else gets most of the benefit with far less uncertainty from tirzepatide, and can read the retatrutide phase 3 results while they wait. Whichever you pick, the 4 week step schedule is what keeps the side effects manageable.
Stacking: Not stacked together; they hit overlapping receptors. Tirzepatide is sometimes paired with ipamorelin in community protocols aimed at lean mass, though no trial supports it.
Retatrutide is a once-weekly peptide that activates GLP-1, GIP and glucagon receptors together. Phase 2 data showed about 24 percent weight loss at 48 weeks, the largest figure reported for any single compound, but it is still years from approval.
Tirzepatide is a once-weekly peptide that activates both the GIP and GLP-1 receptors, producing average weight loss of about 20 percent at the top dose in trials. It is sold as Mounjaro for diabetes and Zepbound for weight management and sleep apnea.
Retatrutide vs Tirzepatide: frequently asked
Is retatrutide stronger than tirzepatide?
On trial averages, yes. Retatrutide produced about 24 percent weight loss at 48 weeks in phase 2 and a reported 28 percent at 80 weeks in TRIUMPH-1, against about 20.9 percent for tirzepatide at 72 weeks. No head to head trial has been published, so the comparison is across different studies, and the retatrutide phase 3 numbers are sponsor reported topline data.
When will retatrutide be approved?
Lilly said in 2026 that it plans to file with the FDA in the first quarter of 2027, so approval is not expected before late 2027 at the earliest. Until then there is no legitimate product.
Can you switch from tirzepatide to retatrutide?
Some people do, but there is no official conversion and no trial data on switching. Community protocols generally start retatrutide at the 1 to 2 mg trial starting dose rather than trying to match tirzepatide milligrams, because the two are not equivalent mg for mg. The heart rate rise should be expected in the first month.
What are the side effects of retatrutide compared to tirzepatide?
The GI effects are similar in kind but reported as rougher in the early weeks with retatrutide, and fast escalation drove most phase 2 dropouts. The distinct retatrutide signals are a resting heart rate increase of several beats per minute and, in a minority, skin tingling. Both carry the class warnings on thyroid C-cell tumors, pancreatitis and gallbladder problems.
Which is better for fat loss, retatrutide or tirzepatide?
Retatrutide produced more total weight loss in trials and had a liver fat substudy where most higher dose participants reached normal liver fat. Whether more of that loss is fat versus lean mass is not yet known; see GLP-1 muscle loss. For an approved option with published data, tirzepatide is the practical choice.
How do the doses compare?
Retatrutide trials started at 1 or 2 mg weekly and stepped every 4 weeks toward 4, 8 or 12 mg. Tirzepatide's label starts at 2.5 mg weekly and increases by 2.5 mg every 4 weeks to a maintenance of 5, 10 or 15 mg. The numbers are not interchangeable; a 4 mg retatrutide dose is not a low dose.
Related reading
Weight loss while limiting muscle loss
Three generations of GLP-1 drugs. What actually separates them?
The two approved GLP-1 drugs went head to head. What does the result mean for you?
First generation versus third. How big is the gap, and what do you give up to close it?
Dosage
Dosage
Sources
- Triple-hormone-receptor agonist retatrutide for obesity, a phase 2 trial. New England Journal of Medicine, 2023
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine, 2022
- TRIUMPH-1 phase 3 topline results for retatrutide (sponsor announcement). Eli Lilly, 2026